Locations:
Search IconSearch
December 7, 2018/Cancer/Tumor Oncology

Breast Reconstruction Complications Not Linked to Breast Cancer Recurrence

Tumor factors are more significant, says new study

Valente-breast-surg_650x450

Immediate breast reconstruction (IBR) after mastectomy is gaining popularity, with approximately 40 percent of breast cancer patients today opting for this approach. While research indicates that IBR has no direct effect on overall or disease-free survival, wound complications following IBR are suspect.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Wound complications can delay adjuvant chemotherapy and radiation therapy, potentially increasing the risk of cancer recurrence. The wound itself also may increase risk — perhaps due to inflammatory response.

At least that’s what some studies indicate.

However, a new study by Cleveland Clinic breast surgeon Stephanie Valente, DO, begs to differ. Recently published in The American Journal of Surgery, Dr. Valente’s retrospective review of 458 women who had IBR at Cleveland Clinic between 2005 and 2010 found that wound complications, and the resulting delay in adjuvant therapy, were not associated with an increase in breast cancer recurrence.

“This study shows that offering a woman immediate breast reconstruction after a mastectomy does not put her at risk of breast cancer recurrence, even if she experiences a wound healing complication,” says Dr. Valente. “However, it also shows that surgical wound complications can delay subsequent treatment (chemotherapy or radiation). Therefore, evaluating patient risk factors for increased complications and making informed decisions is important.”

Complications after surgery

Of the 458 women (median age 49, median follow-up 7.6 years), 100 (22 percent) had one or more wound complications after mastectomy and IBR. That rate is consistent with other published reports, says Dr. Valente.

Complications included:

  • Seroma requiring aspiration (31 patients, 7 percent)
  • Infection requiring intravenous antibiotics (31 patients, 7 percent)
  • Skin flap necrosis requiring surgical debridement (27 patients, 6 percent)
  • Delayed wound healing (22 patients, 5 percent)
  • Loss of implant or tissue flap (14 patients, 3 percent)
  • Hematoma requiring evacuation (11 patients, 2 percent)

Advertisement

According to analyses, the factor most significantly associated with postoperative complication was being overweight. Patients with a body mass index (BMI) of 30 to 35 were 2.9 times more likely to have a complication than patients with a BMI less than 25. Patients with a BMI greater than 35 were 3.5 times more likely.

Patients who had a postsurgical complication did receive adjuvant therapy a median of 11 days later than patients without a complication (52 vs 41 days).

The one factor linked to cancer recurrence

Breast cancer recurred in 42 (9.2 percent) of the study’s 458 women.

On multivariate analysis, the amount of lymph node involvement with metastatic disease was the only statistically significant factor associated with recurrence — not wound complication or delayed adjuvant therapy. Of the patients that had a wound complication, 12 percent had cancer recurrence, compared to 8.4 percent of patients who did not have a wound complication.

Also similar was time to treatment. Patients who had cancer recurrence after a wound complication received adjuvant therapy (either chemotherapy or radiation) a median of 43 days (33-57 days) after surgery. Those who had cancer recurrence but no wound complication received adjuvant therapy a median of 42 days (33-52 days) after surgery.

“Regardless of wound complications, patients in our study received adjuvant therapy within the advised 30- to 60-day treatment window,” says Dr. Valente. “That may explain why there was no difference in cancer recurrence despite the small delay in time to receive adjuvant therapy.”

Advertisement

How to reduce complications after IBR

“There are many factors that determine risk of breast cancer recurrence,” says Dr. Valente. “But our study suggests that the most significant predictor is lymph node involvement, specifically more than four nodes. Surgical wound complications delayed time to subsequent chemotherapy or radiation therapy, but patients were still able to receive treatment in an appropriate time period and, therefore, were not at an increased risk for cancer recurrence.”

Better management of smoking, diabetes and obesity can improve surgical healing outcomes, she says, noting that her study did not associate smoking and diabetes with increased complications because their presence in the cohort was quite small. Prior studies have shown that smoking increases wound complications, so Dr. Valente tends to be more cautious in offering immediate reconstruction to women who actively smoke.

“This study shows that immediate reconstruction after mastectomy for breast cancer is a safe oncologic option,” she says. “It highlights patient modifiable factors, such as obesity, that increase the risk of surgical wound complication, but is reassuring that complications themselves do not increase cancer recurrence.”

Advertisement

Related Articles

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad